Comparative effect of an immunomodulator Immunoxel (DzhereloT™) when used alone or in combination with antiretroviral therapy in drug-naive HIV-infected individuals
by Revaz Chkhetiany, Vladimir Pylipchuk, Olga Argzanova, Nathalia Prihoda, Ludmila Vihrova, Elena Zagaynova, Galina Kutsyna
International Journal of Biotechnology (IJBT), Vol. 9, No. 3/4, 2007

Abstract: Immunomodulating agent Immunoxel (Dzherelo) has been evaluated in 70 HIV-positive individuals divided into three arms: first, control arm, received standard antiretroviral therapy zidovudine/lamivudine/efavirenz (AZT7/3TC/EFV); second-AZT/3TC/EFV+Immunoxel and third, Immunoxel alone, given orally, twice daily. At 32 weeks of follow-up CD4 cell counts increased in all arms, reaching + 102, +190 and +175 cells/mm³, respectively. The proportion of patients who experienced adverse events attributable to study medication was 65%, 24% and 5%. Immunoxel attenuated hepatic toxicity in patients receiving ART as determined by liver function test. Baseline values for ALT aminotransferase were 36, 62 and 72 U/L, which at study conclusion have risen to 78 U/L in arm A, but declined to 38 and 31 U/L in arms B and C. Immunoxel also reversed AIDS-associated wasting. The average weight gain was 1.4, 6.9 and 5.1kg. The results indicate that Immunoxel is safe and exerts beneficial effect in AIDS patients.

Online publication date: Wed, 27-Jun-2007

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email